GTI Reports Q1 2026 Financial Results

CHICAGO – Green Thumb Industries Inc. released its first-quarter 2026 financial results, highlighting steady performance in a market still marked by price competition and variable demand. The multistate Cannabis operator posted steady revenue growth, alongside gains in key profitability measures, solid cash flow from operations, contributions from new store openings, and early impacts from the federal Cannabis rescheduling.

GTI reported Q1 revenue of $300.2 million, a 7.4% increase over the same period in 2025, with cash on hand of $344.5 million at quarter’s end. Retail revenue grew 4.7% year-over-year, driven largely by adult-use sales in Minnesota and continued growth in Connecticut and Florida. Same-store sales, however, dipped 0.5% on a base of 100 stores, with price compression and intensifying competition doing most of the damage.

On the profitability side, GAAP net income came in at $15.4 million, or $0.07 per diluted share, nearly double the $8.3 million recorded in Q1 2025. Normalized EBITDA reached $93.5 million, representing 31.2% of revenue, up from 30.5% a year earlier. Cash flow from operations was $76 million. A one-time arbitration settlement of $17 million and income from a related-party equity investment helped lift the net income line, so investors watching the underlying operational picture should weigh those items accordingly.

The quarter’s most consequential development, however, happened outside the income statement. On April 23, 2026, the U.S. Department of Justice issued a final order immediately rescheduling both FDA-approved Cannabis products and state-regulated medical Cannabis into Schedule III under the Controlled Substances Act, meaning holders of state medical ma licenses are no longer subject to Section 280E of the Internal Revenue Code. For Green Thumb, a company operating across 14 states with a significant medical footprint, this is structural, not cosmetic. CEO Ben Kovler has estimated the change will generate roughly $60 million in additional free cash flow per year, as the business will now be taxed on operating income rather than gross margin.

Management wasted no time acting on the shift. Post-quarter, the company submitted DEA registration applications for certain state-licensed medical operations and was conditionally awarded a Texas Compassionate Use Program license for vertically integrated operations. Texas, with its large population and tightly controlled medical program, represents a slow-burn opportunity — but one Green Thumb has now secured a foothold in.

Capital allocation also continued at pace. The company repurchased approximately 6 million shares during Q1 for $33.3 million, and has bought back roughly 29 million shares totaling $200 million since launching its repurchase program in September 2023. The company also expanded its syndicated credit facility by $50 million during the quarter. With cash exceeding total debt by more than $54 million, the balance sheet gives management room to maneuver.

For shareholders, the key open questions are how quickly DEA registration translates into tangible earnings growth and whether early movers like Green Thumb can widen the competitive gap against smaller or less well-capitalized operators as the Schedule III framework develops.